Literature DB >> 8608209

The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection.

T A Graubert1, J H Russell, T J Ley.   

Abstract

A complete molecular description of the syndromes of graft-versus-host disease (GVHD) and graft rejection could have a significant impact on clinical bone marrow transplantation. Recent in vitro experiments (Heusel et al, Cell 76:977, 1994 and Shresta et al, Proc Natl Acad Sci USA 92:5679, 1995) have shown that the putative mediators of these two syndromes, cytotoxic lymphocytes (CTL) and natural killer (NK) cells, respectively, initiate a program of cell death (apoptosis) in susceptible target tissues in a manner critically dependent on the serine protease Granzyme B (gzm B). In the present study, we have analyzed the phenotype of gzm B-deficient mice using experimental transplant models designed to isolate their CD8+ CTL, CD4+ CTL, and NK compartments. We found a significant impairment in class I-dependent GVHD mediated by gzm B -/- CD8+ CTL, whereas class II-dependent GVHD was not altered using gzm B -/- CD4+ effectors. In a hybrid resistance model, gzm B -/- hosts rejected haplo-identical marrow grafts as efficiently as did their wild-type littermates. This result is surprising in light of a severe defect in the ability of gzm B -/- NK cells to induce apoptosis in susceptible targets in vitro. These in vivo data define significant role for gzm B in cytotoxicity mediated by CD8+ CTL, but not by CD4+ CTL. Furthermore, these results do not support a model of hybrid resistance in which NK cells play a pivotal role.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608209

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

3.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 4.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

5.  Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.

Authors:  Wei Du; Nicholas D Leigh; Guanglin Bian; Rachel E O'Neill; Lin Mei; Jingxin Qiu; George L Chen; Theresa Hahn; Hong Liu; Philip L McCarthy; Xuefang Cao
Journal:  J Immunol       Date:  2015-09-21       Impact factor: 5.422

6.  NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

Authors:  Sanja Vodanovic-Jankovic; Parameswaran Hari; Paulette Jacobs; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

Review 7.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Authors:  Yvonne A Efebera; Susan Geyer; Leslie Andritsos; Sumithira Vasu; Samantha Jaglowski; Anissa Bingman; William Blum; Rebecca Klisovic; Craig C Hofmeister; Don M Benson; Sam Penza; Patrick Elder; Katie Cortright; Rhonda Kitzler; Kevin Coombes; Lynn O'Donnell; Beth Daneault; Hillary Bradbury; Jianying Zhang; Xilin Chen; Sabrina Garman; Parvathi Ranganathan; Xueyan Yu; Jessica Hofstetter; Jianhua Yu; Ramiro Garzon; Scott R Scrape; Gerard Lozanski; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-06       Impact factor: 5.742

9.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

10.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

Authors:  Jacopo Mariotti; Jason Foley; Kaitlyn Ryan; Nicole Buxhoeveden; Veena Kapoor; Shoba Amarnath; Daniel H Fowler
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.